Clinical evidence shows that anti-PD-1/PD-L1 therapies are effective in dMMR/MSI-H colorectal cancers but less so in pMMR/MSS cases, likely due to their immunologically ‘cold’ tumor microenvironment. This evidence concerns the gene CD274 and colorectal cancer.